LPL Financial LLC Buys 2,107 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

LPL Financial LLC raised its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 11.3% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 20,679 shares of the biopharmaceutical company’s stock after acquiring an additional 2,107 shares during the quarter. LPL Financial LLC’s holdings in Alnylam Pharmaceuticals were worth $5,584,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of ALNY. Capital Research Global Investors raised its holdings in Alnylam Pharmaceuticals by 32.9% during the fourth quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company’s stock valued at $1,639,767,000 after acquiring an additional 1,724,610 shares during the period. T. Rowe Price Investment Management Inc. raised its holdings in Alnylam Pharmaceuticals by 39.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company’s stock valued at $1,031,705,000 after acquiring an additional 1,245,195 shares during the period. Marshall Wace LLP raised its holdings in Alnylam Pharmaceuticals by 496.6% during the fourth quarter. Marshall Wace LLP now owns 378,649 shares of the biopharmaceutical company’s stock valued at $89,100,000 after acquiring an additional 315,182 shares during the period. AQR Capital Management LLC raised its holdings in Alnylam Pharmaceuticals by 60.9% during the fourth quarter. AQR Capital Management LLC now owns 813,356 shares of the biopharmaceutical company’s stock valued at $191,391,000 after acquiring an additional 307,702 shares during the period. Finally, Allspring Global Investments Holdings LLC bought a new stake in Alnylam Pharmaceuticals during the first quarter valued at about $69,292,000. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Stock Down 1.2%

Shares of NASDAQ:ALNY opened at $429.93 on Wednesday. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $445.20. The business has a 50 day simple moving average of $336.89 and a two-hundred day simple moving average of $286.99. The firm has a market capitalization of $56.35 billion, a PE ratio of -174.06 and a beta of 0.25. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%. The business had revenue of $773,689 billion during the quarter, compared to analyst estimates of $633.54 million. During the same quarter in the previous year, the business earned ($0.13) earnings per share. The company’s revenue for the quarter was up 17.3% compared to the same quarter last year. On average, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 19,297 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $306.00, for a total transaction of $5,904,882.00. Following the completion of the sale, the chief executive officer owned 48,948 shares of the company’s stock, valued at approximately $14,978,088. The trade was a 28.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 1.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on ALNY. Oppenheimer raised Alnylam Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $490.00 price target on the stock in a report on Monday, August 4th. HC Wainwright raised their price target on Alnylam Pharmaceuticals from $500.00 to $570.00 and gave the company a “buy” rating in a report on Thursday, August 7th. Wells Fargo & Company raised their price objective on Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the company an “equal weight” rating in a research report on Friday, August 1st. Scotiabank raised their price objective on Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the company a “sector outperform” rating in a research report on Friday, August 1st. Finally, Needham & Company LLC raised their price objective on Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the company a “buy” rating in a research report on Thursday, July 31st. Four equities research analysts have rated the stock with a hold rating, twenty-three have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $403.92.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.